At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 24 enrolled
Drug / intervention
Ursodioldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Delayed-Release Ursodeoxycholic Acid on Insulin Sensitivity, Gastric Emptying and Body Weight in Overweight or Obese Patients With Type 2 Diabetes on Metformin Treatment
In Brief
A Phase 2 clinical trial evaluating Ursodiol for Type 2 Diabetes Mellitus. Completed, enrolled 24 participants across 1 site.
Detailed Summary
This study will evaluate whether bile acids are able to increase insulin sensitivity and enhance glycemic control in T2DM patients, as well as exploring the mechanisms that enhance glycemic control. These observations will provide the preliminary data for proposing future therapeutic as well as further mechanistic studies of the role of bile acids in the control of glycemia in T2DM.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartOct 2013
First PostedJan 2014
Primary CompletionJan 2017
Study CompletionMar 2017
TodayJul 2026
First PostedJan 13, 2014
Enrollment StartOct 1, 2013
Primary CompletionJan 1, 2017
Study CompletionMar 1, 2017
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 12.5 years ago
Interventions
Ursodioldrug